Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

Abstract excerpt

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * The interindividual variability of the pharmacokinetic parameters of cilostazol is relatively large. * Cilostazol undergoes extensive hepatic metabolism via the P450 enzymes, primarily CYP3A and, to a lesser extent, CYP2C19. * Indeed, <1% of the administered dose of cilostazol is excreted unchanged in the urine. WHAT THIS STUDY ADDS: * A population pharmacokinetic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aryl Hydrocarbon Hydroxylases
• Share to ATP Binding Cassette Transporter, Subfamily B